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were driven by drug and treatment costs associated with myocardial infarction. The 
total cost of saxagliptin/metformin XR group over 20 years was lower than SU plus 
MET treated group (US$ 14,454,257 vs. US$ 14,735,176). Treatment with saxagliptin/
metformin XR resulted in a greater number of quality-adjusted life years (QALYs) 
and life-years gained (LYG) than the SU combination (10,203 vs. 9,955 and 12,207 vs. 
12,190 respectively). Cost-effectiveness results were robust according to sensitiv-
ity analysis. ConClusions: according to the model cost-effectiveness results in 
Colombia, saxagliptin/metformin XR FDC would be the dominant treatment option 
compared to SU as add-on to MET, for people with T2DM after failure of treatment 
only with MET.
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objeCtives: CANA and DAPA are sodium glucose co-transporter 2 inhibitors indi-
cated for the treatment of adults with T2DM as monotherapy and as add-on combi-
nation therapy with other antihyperglycemic agents. The objective of this analysis 
was to evaluate the cost-effectiveness of using CANA 300mg versus using DAPA 
10mg in dual therapy (with MET background) in patients with inadequate A1C 
control. Methods: A validated health economics model, Economic and Health 
Outcomes (ECHO)–T2DM, was used to estimate 30-year outcomes associated with 
using each treatment in patients as an add-on to MET monotherapy. Treatment 
effects for A1C, weight and the probability of hypoglycemia were obtained from 
a Bayesian Network Meta-Analysis (NMA) of 52 (+/-4) week trials of subjects 
inadequately controlled on MET monotherapy. For parameters unavailable in the 
NMA (i.e., SBP, LDL, HDL and rates of AEs), values were obtained from a post-hoc 
analysis of pooled data from two trials of subjects receiving CANA and MET. In 
the model, treatment was intensified when A1C exceeded 7.5%, first by adding 
basal insulin and subsequently by adding prandial insulin. Utility decrements and 
U.S. costs associated with key macrovascular and microvascular heath states and 
AEs were sourced from the literature. All costs and benefits were discounted at 
3%. Results: CANA dominated DAPA; CANA was associated with both cost sav-
ings ($3,204) and more Quality Adjusted Life Years (0.22). The reductions in the 
relative risks of microvascular (up to 4.4%) and macrovascular events (up to 1.7%) 
as well as a delay in the use of insulin are the key drivers. ConClusions: This 
simulation suggests that CANA will not only produce cost-savings, but also result 
in QALY gains versus DAPA in the treatment of patients inadequately controlled 
on MET in the US.
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objeCtives: To compare the cost-effectiveness of dapagliflozin versus sulfony-
lurea (SU) added to metformin in people with T2DM inadequately controlled on 
metformin alone, in Argentina and Chile. Methods: A discrete event simulation 
model (Cardiff diabetes model) based on UKPDS 68 was used to simulate disease 
progression and to estimate the economic and health treatment consequences in 
people with T2DM. Epidemiologic and clinical efficacy parameters were obtained 
from the literature. The cost of medication was based on country level drug prices; 
the cost of macro- and microvascular events was based on tariffs from the social 
security system of Argentina and the National Health Insurance (FONASA) of Chile. 
Costs were expressed in US dollars ($). A 20-year time horizon and the payer’s per-
spective were assumed. Costs and health outcomes were discounted at 5% and 
3% in Argentina and Chile, respectively. Deterministic and probabilistic sensitivity 
analyses (PAS) were performed. Results: Comparison of dapagliflozin add-on to 
metformin versus SU addition to metformin showed an incremental benefit of 0.376 
QALYs (95%CI: 0.368; 0.385) in Argentina and 0.422 QALYs (95%CI: 0.411; 0.432) in 
Chile. In both countries, the total cost of the dapagliflozin cohort was higher than 
that of the SU cohort (Incremental cost: Argentina: $3,400; Chile: $2,423). The calcu-
lated Incremental Cost-Effectiveness Ratio (ICER) was $9,036 and $5,745 per QALY 
in Argentina and Chile, respectively. Using WHO’s criteria, dapagliflozin compared 
to the SU treatment strategy has 88% probability for Argentina and 99% for Chile 
of being highly cost-effective (ICER< 1 GDP per capita). The results were robust to 
sensitivity analysis. ConClusions: Dapagliflozin in combination with metformin 
is a cost-effective treatment option for patients who are inadequately controlled 
with metformin monotherapy in Argentina and Chile.
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objeCtives: Determine the cost-effectiveness of becaplermin gel* on wound heal-
ing and amputation for the treatment of diabetic foot ulcers (DFUs). Methods: 
A 4-stage Markov model was used to predict the expected costs and outcomes 
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objeCtives: Determine the cost-effectiveness of clostridial collagenase ointment 
(CCO) plus surgical sharp debridement (SSD) relative to the standard of care (SC) plus 
SSD on wound closure for the treatment of diabetic foot ulcer (DFU). SC was defined 
as offloading plus daily wound care/dressings. Methods: A 3-stage Markov model 
was used to predict the expected costs and outcomes of wound closure for CCO and 
SC. The 3 stages were open wound, epithelialization, and death. Outcome data used 
in the analysis were taken from a randomized clinical trial that directly compared 
CCO and SC. The primary outcome was the proportion of patients achieving a closed 
epithelialized wound. Transition probabilities for the Markov states were estimated 
from the clinical trial. A 52-week time horizon was used to determine the number of 
closed epithelialized wounds and the expected costs for the two therapies. Resource 
utilization was based on the treatment regimen used in the clinical trial. Costs 
were derived from standard cost references and medical supply wholesalers. The 
economic perspective taken was that of the payer. Results: A total of 55 patients 
were included (28 for CCO and 27 for SC). Expected direct costs per patient for DFU 
were $2099 for CCO and $2376 for SC (a cost-savings of $278 for CCO). Patients 
treated with CCO had, on average, 35 ulcer-free weeks compared to 28 weeks for SC. 
CCO therapy had a higher probability of healing at 52 weeks compared to SC (89% 
vs. 80%, respectively). The cost per closed wound week was 1.4 times higher for SC 
compared to CCO ($61/week versus $85/week, respectively). ConClusions: CCO 
was cost-effective over SC, yielding better outcomes at a lower cost in patients with 
DFU. Health care providers should consider CCO as a more effective alternative to 
SC and an effective adjunct therapy to sharp debridement.
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objeCtives: To evaluate the cost-effectiveness of canagliflozin in dual therapy (plus 
metformin) compared to sitagliptin and glimepiride, and in triple therapy compared 
to pioglitazone (plus metformin), sitagliptin (plus glimepiride and metformin) and as 
add on to insulin (plus metformin) respectively in the Belgian setting from the public 
payers perspective. Methods: The IMS CORE Diabetes Model was used to evaluate, 
based on head-to-head clinical trials, the cost-effectiveness of canagliflozin (assum-
ing 70/30 dose distribution for the 100mg and 300mg respectively) versus the afore-
mentioned comparators using Belgian-specific data, where available. Costs were 
obtained from official sources, literature and the IMS Hospital Disease Database and 
are reported in 2013 Euro (€ ).An annual discount rate of 3% was applied on costs 
and 1.5% on effects. Results: The cost-effectiveness analyses indicate that in dual 
therapy when compared with sitagliptin and glimepiride, canagliflozin is expected 
to be cost–effective with an ICER of 6,992 € /QALY gained (with an incremental cost 
and QALY of € 366 and 0.052) and 3,364 € /QALY gained (with an incremental cost 
and QALY of € 410 and 0.122), respectively. In both triple therapies, treatment with 
canagliflozin appears to be a dominant strategy resulting in QALY gains and cost-
savings. As an add on to insulin (plus metformin), canagliflozin is cost–effective with 
an ICER of 11,929 € /QALY gained (with an incremental cost and QALY of € 721 and 
0.060). The deterministic sensitivity analysis revealed that the results are sensitive 
to time horizon (with a time horizon of 10 years the ICER increases to a level in range 
€ 20.000-30.000). Probabilistic sensitivity analysis showed that in all the comparisons, 
canagliflozin appears to be the dominant strategy with a large proportion (about 
48%) of cases being in the south-east quadrant. ConClusions: Canagliflozin 100 
mg or 300 mg (70/30 dose split) provides economic value when used in treatment 
of type 2 diabetes in Belgium.
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objeCtives: To evaluate the economic impact of using saxagliptin/metformin XR 
FDC versus sulfonylurea (SU) plus metformin (MET) in Colombia, in people with type 
2 diabetes (T2DM) who do not achieve treatment goal only with MET. Methods: A 
discrete event simulation model (Cardiff diabetes model) based on UKPDS 68 was 
used to simulate disease progression and to estimate the economic and health 
treatment consequences in people with T2DM. Epidemiologic and clinical efficacy 
parameters were obtained from the literature. Cost of medication was obtained 
from country level drug prices, SISMED and Farmaprecios; cost of macro and micro-
vascular events were based on POS tariffs, SOAT Manual and consultation with a 
local expert. A 20-year time horizon was assumed. Costs and health outcomes were 
discounted at 3% annually. Deterministic and probabilistic sensitivity analysis were 
also performed. Results: The group treated with saxagliptin/metformin XR had 
fewer non-fatal events and episodes of hypoglycemia than the SU plus MET treated 
group. The model also predicted a lower number of fatal macrovascular events for 
the saxagliptin/metformin XR group (159 vs. 162). In both treatment groups the costs 
